Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Environmental Science & Technology
|
June 12, 2012
Early public impressions of terrestrial carbon capture and storage in a coal-intensive state
Sanya R Carley, Rachel M Krause, David C Warren, et al.
Risk Analysis : an Official Publication of the Society for Risk Analysis
|
October 15, 2013
"Not in (or under) my backyard": Geographic proximity and public acceptance of carbon capture and storage facilities
Rachel M Krause, Sanya R Carley, David C Warren, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
October 9, 2002
Assessing preferences for prevention versus treatment using willingness to pay
Phaedra S Corso, James K Hammitt, John D Graham, et al.
Optics Express
|
February 23, 2010
Tunable negative group index in metamaterial structures with large form birefringence
Kirill Sinchuk, Richard Dudley, John D Graham, et al.
Optics Express
|
January 26, 2011
Internal field distribution measurement in 1-D strongly anisotropic sub-wavelength periodic structures of finite length
Mesfin Woldeyohannes, John O Schenk, Robert P Ingel, et al.
European Urology
|
January 9, 2018
Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial
Antoine Kass-Iliyya, Gordana Jovic, Claire Murphy, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 30, 2007
The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397)
David P Dearnaley, Matthew R Sydes, Ruth E Langley, et al.
The Lancet. Oncology
|
March 4, 2014
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial
David P Dearnaley, Gordana Jovic, Isabel Syndikus, et al.
The Lancet. Oncology
|
May 8, 2007
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
David P Dearnaley, Matthew R Sydes, John D Graham, et al.
Lancet (London, England)
|
January 1, 2016
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D James, Matthew R Sydes, Noel W Clarke, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Environmental Science & Technology
|
June 12, 2012
Early public impressions of terrestrial carbon capture and storage in a coal-intensive state
Sanya R Carley, Rachel M Krause, David C Warren, et al.
Risk Analysis : an Official Publication of the Society for Risk Analysis
|
October 15, 2013
"Not in (or under) my backyard": Geographic proximity and public acceptance of carbon capture and storage facilities
Rachel M Krause, Sanya R Carley, David C Warren, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
October 9, 2002
Assessing preferences for prevention versus treatment using willingness to pay
Phaedra S Corso, James K Hammitt, John D Graham, et al.
Optics Express
|
February 23, 2010
Tunable negative group index in metamaterial structures with large form birefringence
Kirill Sinchuk, Richard Dudley, John D Graham, et al.
Optics Express
|
January 26, 2011
Internal field distribution measurement in 1-D strongly anisotropic sub-wavelength periodic structures of finite length
Mesfin Woldeyohannes, John O Schenk, Robert P Ingel, et al.
European Urology
|
January 9, 2018
Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial
Antoine Kass-Iliyya, Gordana Jovic, Claire Murphy, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
March 30, 2007
The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: results from the MRC RT01 trial (ISRCTN47772397)
David P Dearnaley, Matthew R Sydes, Ruth E Langley, et al.
The Lancet. Oncology
|
March 4, 2014
Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial
David P Dearnaley, Gordana Jovic, Isabel Syndikus, et al.
The Lancet. Oncology
|
May 8, 2007
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
David P Dearnaley, Matthew R Sydes, John D Graham, et al.
Lancet (London, England)
|
January 1, 2016
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas D James, Matthew R Sydes, Noel W Clarke, et al.
Page
of 3